Hepatitis control must be accelerated
Hep-Core Report 2016

Study

Hepatitis control must be accelerated

Last year the WHO launched a global strategy on viral hepatitis aiming to eliminate hepatitis B (HBV) and C (HCV) as public health threats by 2030.

Report: Sylvia Schulz

Among the goals: a 90% drop in the number of chronically infected people and a 65% mortality rate reduction, as untreated chronic viral hepatitis can cause irreversible liver damage leading to cirrhosis or Cancer.

The global health organisation, clearly demonstrating that  hepatitis is not only a problem among third world countries but is also a  current European issue, set up an action plan last September. Europe  records around 57,000 newly diagnosed acute and chronic cases of  hepatitis B and C annually. On top of that, an estimated 10 million  Europeans are believed to have chronic hepatitis B and C infections  without knowing it or being treated.

As the monitoring  and evaluation framework of the WHO hepatitis strategy is not expected  to become operational until 2018, the European Liver Patients  Organisation (ELPA) surges ahead, compiling facts about state of the art  care concerning this disease. It commissioned a broadly based, the  Hep-CORE study, to shed light on the policy response to hepatitis B and C  engaging with ELPA member organisations.

Based at the  University of Barcelona and Copenhagen, the research team carried out  the survey, with data collected from local specialists in each country.  The researchers asked one patient group in each of ELPA’s 27  member-countries to complete a 39-item survey about various aspects  relating to HBV and HCV: overall national response, public awareness and  engagement, disease monitoring and data collection, prevention, testing  and diagnosis, clinical assessment, and treatment. The plan is to  repeat the patient-led monitoring tool on a regular basis, to compare  results between countries and follow individual country progress over  time.

In brief, the study reveals serious gaps in  policies concerning hepatitis control. 52 per cent of the 27 European  countries surveyed lack national strategies to address viral hepatitis B  or C despite the WHO’s Assembly resolution calling on all countries to  have one. Only three of those countries have access to the new, highly  effective medicines (direct-acting antivirals) for hepatitis C without  restrictions. The director of studies, Professor Jeffrey V Lazarus, from  the University of Barcelona, said: ‘These Hep-CORE results serve as an  unprecedented analysis of regional and national gaps, clearly showing  where there are deficient policies and, by default, what action needs to  be taken.’

No national register

Viral hepatitis must be combated on a large scale

Professor Jeffrey V Lazarus

For example, despite an urgent need for broad monitoring and disease surveillance, this study found that 17 countries (63%) have no national hepatitis B virus (HBV) register and 15 countries (56%) have no national hepatitis C virus (HCV) register. Basic access to testing and screening facilities is vital for patients, especially those from high-risk groups, such as people who inject drugs, or prisoners.

Despite this, patient groups from 10 countries (37%) reported that there are no HCV testing or screening sites outside of hospitals for the general population in their countries. Even more alarming, patient groups from 12 of the countries (44%) reported that there are no such sites outside of hospitals that provide testing or screening services for high-risk populations.

Another section of the survey asked a set of questions oriented towards understanding hepatitis prevention in each country. This section focused on the availability of harm reduction –  services that target the reduction of negative health consequences associated with drug use, such as the spread of viral hepatitis.

It was reported that clean needle and syringe programmes are available in at least one area of a patient group’s country in 22 cases (81%), that opioid substitution therapy is available in at least one area of a patient group’s country in 24 cases (89%), and that drug consumption rooms are available in only five cases (19%). The study shows that significant gaps in harm reduction regarding reported coverage and availability remain.

Lazarus concludes: ‘The 2016 Hep-CORE Report findings are a resource that can aid the efforts of all those working to eliminate HBV and HCV as public health threats in Europe, and beyond, in line with WHO’s global strategy. We now have a starting point from which we can systematically scale up hepatitis prevention, treatment, and care – and monitor the much-needed progress. Viral hepatitis must be combated on a large scale and this requires individual country and concerted pan-European action.’

20.04.2017

Read all latest stories

Related articles

World Sepsis Day 2018

Beckman Coulter sponsored 2nd World Sepsis Congress

Beckman Coulter was a gold sponsor of the 2nd World Sepsis Congress, a free-of-charge online conference, hosted by the Global Sepsis Alliance, that took place on Sept. 5 and 6, 2018. Over the course…

T cell response

Scientists find out what makes people survive Ebola

Scientists conducting the first comprehensive study of key immune system cells—collected from West African Ebola survivors— have made a surprising discovery that provides important clues to…

Terror protection

Promising vaccines against anthrax, plague and tularemia

Anthrax, plague and tularemia are three potent agents terrorists would be likely to use in an attack, according to the Centers for Disease Control and Prevention. Each is highly and quickly lethal to…

Related products

Infectious diseases testing

Atlas Genetics - Atlas Genetics io system

Atlas Genetics Ltd

LIS, Middleware, POCT

Beckman Coulter - PROService

Beckman Coulter, Inc.

Specialties

COMED - RMS / SHS-WEB / SHS Mobile App / E-Commerce (B2B)

COMED Computerorganisation in der Medizin GmbH

LIS, Middleware, POCT

Siemens Healthineers - syngo Lab Inventory Manager (sLIM)

Siemens Healthineers